CRVS Latest Headlines

Corvus Pharmaceuticals Schedules Investor Presentations at Major 2026 Healthcare Conferences—What’s Behind the Spotlight?

Market Chameleon (Thu, 21-May 9:00 AM)

Corvus Pharmaceuticals' Soquelitinib Shows Durable Remissions and Safety in Atopic Dermatitis Phase 1 Trial

Market Chameleon (Fri, 15-May 11:23 AM)

Corvus Pharmaceuticals’ Soquelitinib Shows Durable, Drug-Free Remission in Atopic Dermatitis Phase 1 Trial

Market Chameleon (Thu, 14-May 10:37 AM)

Soquelitinib Phase 1 Data Shows Durable, Drug-Free Remissions for Atopic Dermatitis Patients

Market Chameleon (Thu, 14-May 7:56 AM)

Corvus Pharmaceuticals to Spotlight Soquelitinib’s Drug-Free Remission Data at Investor Meeting on May 14, 2026

Market Chameleon (Tue, 21-Apr 8:21 AM)